Research in Finland was conducted in order to evaluate the effects of three potentially anti-inflammatory probiotic bacteria from three different genera on immune variables in healthy adults in a clinical setting based on previous in vitro characterization of cytokine responses.
A total of 62 volunteers participated in this randomized, double-blind and placebo-controlled parallel group intervention study on probiotics.
The volunteers were randomized to receive a milk-based drink containing one probiotic
- Lactobacillus Rhamnosus GG (LGG),
- Bifidobacterium animalis ssp. lactis Bb12 (Bb12), or
- Propionibacterium freudenreichii ssp. shermanii JS (PJS) or
- a placebo drink
for 3 weeks.
Venous blood and saliva samples were taken at baseline and on d 1, 7 and 21.
Fecal samples were collected at baseline and at the end of intervention.
Result: The serum hsCRP expressed as the median AUC(0-21) (minus baseline) was 0.018 mg/L in the placebo group, -0.240 mg/L in the LGG group, 0.090 mg/L in the Bb12 group and -0.085 mg/L in the PJS group (P = 0.014). In vitro production of TNF-alpha from in vitro cultured peripheral blood mononuclear cells (PBMC) was significantly lower in subjects receiving LGG vs placebo. IL-2 production from PBMC in the Bb12 group was significantly lower compared with the other groups.
Probiotic bacteria have strain-specific anti-inflammatory effects in healthy adults.
Source: University of Helsinki, Institute of Biomedicine, Pharmacology, Helsinki, Finland, posted on Apr 7, 2008
Authors: Kekkonen RA, Lummela N, Karjalainen H, Latvala S, Tynkkynen S, Jarvenpaa S, Kautiainen H, Julkunen I, Vapaatalo H, Korpela R.
(*) Kekkonen RA, Lummela N, Karjalainen H, Latvala S, Tynkkynen S, Jarvenpaa S, Kautiainen H, Julkunen I, Vapaatalo H, Korpela R.